Contrasting enVVeno Medical (NASDAQ:NVNO) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN)

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Inspira Technologies OXY B.H.N. and enVVeno Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1	0	1	0	2.00
enVVeno Medical	1	1	0	0	1.50

Inspira Technologies OXY B.H.N. presently has a consensus price target of $2.00, suggesting a potential upside of 365.12%. Given Inspira Technologies OXY B.H.N.’s stronger consensus rating and higher possible upside, research analysts plainly believe Inspira Technologies OXY B.H.N. is more favorable than enVVeno Medical.

Earnings & Valuation

This table compares Inspira Technologies OXY B.H.N. and enVVeno Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$290,000.00	53.31	-$13.22 million	N/A	N/A
enVVeno Medical	N/A	N/A	-$19.47 million	($37.89)	-0.26

Inspira Technologies OXY B.H.N. has higher revenue and earnings than enVVeno Medical.

Profitability

This table compares Inspira Technologies OXY B.H.N. and enVVeno Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
enVVeno Medical	N/A	-62.98%	-57.32%

Volatility and Risk

Inspira Technologies OXY B.H.N. has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 15.0% of enVVeno Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Inspira Technologies OXY B.H.N. beats enVVeno Medical on 9 of the 10 factors compared between the two stocks.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.